HGF/c-MET Pathway in AIDS-Related Lymphoma
Technical Report,15 Aug 2015,14 Aug 2019
Louisiana State University Health Sciences Center New Orleans United States
Pagination or Media Count:
During the whole funding period 2015-2018, we have completed all the 3 Specific Aims as listed in the SOW forms above. Our results have illuminated the complicated mechanisms through which the HGFc-MET pathway regulates KSHV PEL cell survival. Our exciting in vivo data have provided the framework for development and implementation of clinical trials for evaluating strategies targeting HGFc-MET alone or combination of other therapies for the treatment of lymphoma in HIV-infected patients including military personnel. Until January 2019, we have totally published 25 peer-reviewed articles about the molecular mechanisms of KSHV viral oncogenesis, and developing novel therapeutic strategies against these malignancies. In most of these publications, I am served as the corresponding or co-corresponding author. We also have published 9 meeting abstracts on national or international meetings. With the support by this DOD award, I have obtained several intramural and extramural funding, including a NIHNCI RO1 funding as PI and a NIH COBRE subproject as the project leader.
- Medicine and Medical Research